The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OGEN | -91.44% | -99.96% | -79.19% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +592% |
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.
No news articles found for Oragenics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $5.41M | 51.1% |
| Market Cap / Employee | $1.80M | 0.0% |
| Employees | 3 | 0.0% |
| Net Income | -$3,066.59K | -24.5% |
| EBITDA | -$3,123.77K | -28.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.40M | 262.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $394.84K | -24.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -121.78% | 183.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,984.52K | -51.5% |
| Operating Free Cash Flow | -$2,984.52K | -51.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -21.91 | 32.75 | 19.86 | -0.51 | -121.02% |
| Price to Sales | 244.04 | 630.89 | - | ||
| Price to Tangible Book Value | 70.04 | -373.75 | 19.86 | -0.51 | -99.79% |
| Enterprise Value to EBITDA | -1.22 | -1.46 | -2.23 | 2.87 | -580.18% |
| Return on Equity | -417.1% | -714.9% | -748.0% | -168.9% | -62.85% |
| Total Debt | $328.53K | $2.55M | $3.00M | $394.84K | -23.98% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
